Related Experiment Videos
ZD1839 (Iressa): for more than just non-small cell lung cancer
1Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom. malcolm.ranson@man.ac.uk
Abstract:
ZD1839 (Iressa) is an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor that blocks signal transduction pathways involved in cell proliferation. Preclinical studies demonstrated that ZD1839 is a promising agent for the treatment of a wide range of tumors and has additive-to-synergistic effects when combined with radiation or chemotherapy in various cell lines and xenografts. Phase I clinical trials have reported that ZD1839 has acceptable tolerability and antitumor activity. In addition to non-small cell lung cancer, phase II/III studies are currently investigating ZD1839 as monotherapy or in combination therapy against prostate, breast, head and neck, gastric, and colorectal tumors.
Insights
ZD1839 (Iressa) is a targeted therapy blocking cancer cell growth. Clinical trials show it is well-tolerated and effective against various tumors, including non-small cell lung cancer.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Epidermal Growth Factor Receptor (EGFR) signaling pathways are crucial for cell proliferation and are often dysregulated in various cancers.
- ZD1839 (Iressa) is a selective EGFR tyrosine kinase inhibitor designed to block these critical signaling pathways.
- Preclinical data suggest ZD1839 has potential as a therapeutic agent for multiple tumor types.
Purpose of the Study:
- To evaluate the efficacy and tolerability of ZD1839 (Iressa) as a monotherapy and in combination treatments.
- To explore the potential of ZD1839 in treating a broad spectrum of solid tumors beyond non-small cell lung cancer.
Main Methods:
- Preclinical evaluation in cell lines and xenografts to assess efficacy with radiation and chemotherapy.
- Phase I clinical trials to determine tolerability and preliminary antitumor activity.
- Ongoing Phase II/III clinical studies investigating ZD1839 in various cancer types.
Main Results:
- Preclinical studies indicated additive-to-synergistic effects when ZD1839 was combined with radiation or chemotherapy.
- Phase I trials demonstrated acceptable tolerability and demonstrated antitumor activity of ZD1839.
- Ongoing studies are assessing ZD1839 in non-small cell lung cancer, prostate, breast, head and neck, gastric, and colorectal cancers.
Conclusions:
- ZD1839 (Iressa) is a well-tolerated EGFR tyrosine kinase inhibitor with demonstrated antitumor activity.
- Its potential therapeutic applications extend to a wide range of solid tumors, both as monotherapy and in combination regimens.
- Further clinical investigation is warranted to establish its role in diverse oncological settings.